Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 25 November 2022, including: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK plc; uniQure N.V./CSL Limited's gene therapy sets record US price; new leadership at Teva Pharmaceutical Industries Ltd.; and Merck & Co., Inc.’s Frazier cautions against profit maximization.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure" - Scrip, 22 Nov, 2022.)
(Also see "Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes" - Scrip, 22 Nov, 2022.)
(Also see "UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price" - Scrip, 23 Nov, 2022.)
(Also see "Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization" - Scrip, 21 Nov, 2022.)
(Also see "Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization" - Scrip, 21 Nov, 2022.)